drugset / Trial / NCT07269210
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipid measures compared to placebo in participants with severe hypertriglyceridemia. Participants will receive two subcutaneous injections.
Timeline
- Start
- 2025-12-08
- Primary completion
- 2027-03
- Completion
- 2027-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Solbinsiran | Unknown | — | Subcutaneous |
Indications
No indication recorded.